江苏天瑞仪器股份有限公司独立董事提名人声明 提名人江苏天瑞仪器股份有限公司董事会现就提名莫卫民为江苏天瑞仪器 股份有限公司第六届董事会独立董事候选人发表公开声明。被提名人已书面同 意出任江苏天瑞仪器股份有限公司第六届董事会独立董事候选人。本次提名是 在充分了解被提名人职业、学历、专业资格、详细的工作经历、全部兼职等情 况后作出的，本提名人认为被提名人符合相关法律、行政法规、部门规章、规 范性文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要 求，具体声明如下： 一、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得 担任公司董事的情形。 是 □否 如否，请详细说明：______________________________ 二、被提名人符合中国证监会《上市公司独立董事规则》规定的独立董事任 职资格和条件。 是 □否 如否，请详细说明：______________________________ 三、被提名人符合公司章程规定的独立董事任职条件。 是 □否 如否，请详细说明：______________________________ 四、被提名人已经参加培训并取得证券交易所认可的相关 ...

经全体监事认真审议，形成决议如下： 证券代码：300165 证券简称：天瑞仪器 公告编号：2023-066 江苏天瑞仪器股份有限公司 第五届监事会第十四次（临时）会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 江苏天瑞仪器股份有限公司（以下简称"公司"）于 2023 年 8 月 11 日以电 子邮件方式向全体监事发出召开第五届监事会第十四次（临时）会议的通知，会 议于 2023 年 8 月 14 日上午 10：00 在公司八楼会议室以现场会议的方式召开。 会议应出席监事3人，实际出席监事3人。公司代行董事会秘书列席了会议。会 议由监事会主席徐应根召集和主持，会议的召开符合有关法律、行政法规、部 门规章、规范性文件和《公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于公司监事会提前换届选举暨提名第六届监事会非职工 代表监事候选人的议案》 公司第五届监事会原定任期至 2024 年 5 月 12 日届满。因广州立多虚拟现实 科技合伙企业（有限合伙）持有公司股份 24,825,137 股，占公司总股本 5.01%, ...

二、关于公司董事会提前换届选举暨提名第六届董事会独立董事候选人的 独立意见 公司第五届董事会原定任期至 2024 年 5 月 12 日届满。本次进行换届选举符 合相关法律、法规、规范性文件及《公司章程》的有关规定，本次董事会独立董 事换届选举审议和表决程序合法合规，不存在损害股东合法利益，尤其是中小股 东合法利益的情形。本次提名的公司第六届董事会独立董事候选人莫卫民先生、 张鑫先生、钱宇瑾女士不存在《公司法》第一百四十六条规定不得担任公司董事 的情形，不存在《公司法》、《上市公司独立董事规则》、《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》中规定的不得担任上市公 司独立董事的情形，不存在被中国证监会确定为市场禁入者且尚未解除的情况， 未曾受到中国证监会和证券交易所的处罚或惩戒，亦不是失信被执行人，具备担 任上市公司独立董事的任职资格和能力。 根据《上市公司独立董事规则》、《深圳证券交易所创业板股票上市规则》、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 以及江苏天瑞仪器股份有限公司（以下简称"公司"）《公司章程》、《独立董事工 作制度》等相关法律法 ...

江苏天瑞仪器股份有限公司独立董事候选人声明 声明人莫卫民作为江苏天瑞仪器股份有限公司第六届董事会独立董事候选 人，现公开声明和保证，本人与该公司之间不存在任何影响本人独立性的关系， 且符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规 则对独立董事候选人任职资格及独立性的要求，具体声明如下： 一、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担任 公司董事的情形。 是 □否 如否，请详细说明：______________________________ 二、本人符合中国证监会《上市公司独立董事规则》规定的独立董事任职资 格和条件。 是 □否 如否，请详细说明：______________________________ 三、本人符合该公司章程规定的独立董事任职条件。 五、本人担任独立董事不会违反《中华人民共和国公务员法》的相关规定。 是 □否 如否，请详细说明：______________________________ 六、本人担任独立董事不会违反中共中央纪委《关于规范中管干部辞去公职 或者退（离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的 相关规定。 是 □否 ...

证券代码：300165 证券简称：天瑞仪器 公告编号：2023-067 江苏天瑞仪器股份有限公司 第五届董事会第十八次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏天瑞仪器股份有限公司（以下简称"公司"）于 2023 年 8 月 11 日以电 子邮件方式向全体董事发出召开第五届董事会第十八次（临时）会议的通知。会 议于 2023 年 8 月 14 日下午 3:00 在公司八楼会议室以现场表决和通讯表决相结 合的方式召开。会议应出席董事 8 人，实际出席董事 8 人（其中：独立董事汪进 元先生、独立董事莫卫民先生、独立董事张鑫先生以通讯表决方式出席本次会议）。 公司监事及高级管理人员列席了会议。本次会议的召集、召开程序符合《中华人 民共和国公司法》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》、《公司章程》等有关规定。会议由董事长刘召贵先生主持。 二、董事会会议审议情况 经与会董事认真审议，形成如下决议： 为确保董事会的正常运作，在新一届董事会非独立董事就任前，原非独立董 事仍应 ...

证券代码：300165 证券简称：天瑞仪器 公告编号：2023-064 江苏天瑞仪器股份有限公司 减持股份达到 1%的更正公告 公司控股股东、实际控制人、董事长刘召贵先生及其一致行动人杜颖莉女 士、上海牧鑫私募基金管理有限公司－牧鑫天泽汇4号私募证券投资基金保证向 本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 | 股东名称 | 变动方式 | | | 变动时间 | | | 减持均价 | 变动股数 | 变动比例（%） | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | （元） | （股） | | | 刘召贵 | 大宗交易 | 2023 | 年 | 7 月 | 12 | 日 | 5.97 | 1,798,000 | 0.3629 | 关于控股股东、实际控制人、董事长刘召贵先生及其一致行动人 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 江苏天瑞仪器股份有限公司于 2023 年 7 月 14 日披露了《关于控股股东、实 际控制人、董事长刘召贵先生及其一致行 ...

江苏天瑞仪器股份有限公司 关于控股股东、实际控制人、董事长刘召贵先生及其一致行动人 减持股份达到 1%的公告（更新后） 证券代码：300165 证券简称：天瑞仪器 公告编号：2023-065 | 信息披露义务人1 | 刘召贵先生 | | | | --- | --- | --- | --- | | 住所 | 江苏省昆山市**** | | | | 信息披露义务人2 | 杜颖莉女士 | | | | 住所 | 江苏省昆山市**** | | | | 信息披露义务人3 | 上海牧鑫私募基金管理有限公司－牧鑫天泽汇4号私募证券投资 | | | | | 基金 | | | | 住所 | 上海市崇明区长兴镇潘园公路1800号2号楼5809室（上海泰和经 | | | | | 济发展区） | | | | 权益变动时间 | 2023年7月12日 | | | | 股票简称 天瑞仪器 | 股票代码 | | 300165 | | 变动类型（可 增加□ 减少 | 一致行动人 | 有 | 无□ | | 多选） | | | | | 是否为第一大股东或实际控制人 | | 是 否□ | | | 2.本次权益变动情况 | | | | | 股份种类 ...

Financial Performance - The company's revenue for the third quarter reached ¥525,268,787.75, representing a 122.91% increase compared to the same period last year[4]. - The net profit attributable to shareholders was -¥13,883,941.52, a decrease of 133.59% year-on-year[4]. - The company reported a basic earnings per share of -¥0.0256, down 128.60% from the same period last year[4]. - The net profit for Q3 2021 was CNY 984,176.03, a significant decrease from CNY 19,600,254.19 in the same period last year, representing a decline of approximately 95%[32]. - The total operating profit for Q3 2021 was CNY 11,443,518.39, down from CNY 34,988,374.98 in Q3 2020, indicating a decrease of about 67%[31]. - The company experienced a total comprehensive income of CNY 984,176.03 for Q3 2021, down from CNY 19,600,254.19 in the previous year, reflecting a decline in overall financial performance[32]. Cash Flow - The cash flow from operating activities showed a significant improvement, with a net amount of -¥277,162,184.18, reflecting a 349.19% increase from the previous year[4]. - Net cash flow from operating activities was -27,716.22 million, a decline of 349.19% from -6,170.31 million, primarily due to increased procurement and operational payments related to PPP projects[13]. - The cash flow from operating activities showed a net outflow of CNY 277,162,184.18, compared to a net outflow of CNY 61,703,060.39 in the previous year, reflecting a worsening cash flow situation[35]. - The company reported a total cash inflow from financing activities of CNY 723,262,166.51, compared to CNY 276,190,326.85 in the previous year, indicating a significant increase in financing activities[36]. - The cash outflow from investing activities was CNY 509,620,687.28, up from CNY 309,015,599.95 in the same period last year, showing increased investment expenditures[35]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,314,082,791.20, an increase of 29.23% compared to the end of the previous year[4]. - Total assets increased to CNY 3,314,082,791.20 from CNY 2,564,439,469.59, showing strong growth in the company's financial position[26]. - Total liabilities rose to CNY 1,578,546,669.74, up from CNY 825,379,245.12, indicating increased leverage[27]. - The company's equity totaled CNY 1,739,060,224.47, with a decrease of CNY 482,930.39[41]. Investments and R&D - The company has seen a 153.14% increase in prepayments, totaling ¥20,988.65 million, primarily due to materials procurement[10]. - R&D expenses rose by 37.55% to 5,536.75 million from 4,025.31 million, driven by an increase in R&D projects[12]. - The company is actively developing new products, including a flu virus antigen detection kit, which has increased capitalized development expenditures by 67.96%[10]. - The company has a significant focus on research and development in biological feed and organic fertilizers, indicating a strategic shift towards sustainable products[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,884[15]. - The largest shareholder, Liu Zhaogui, holds 29.04% of the shares, totaling 144,326,306 shares[15]. - The total number of restricted shares held by executives and related parties is 202,211,509, with 171,106,061 shares still under restriction[21]. - The company reported a total of 13,634,389 restricted shares held by various counterparties, which will not be transferred within 12 months[21]. Government Subsidies and Income - The company received government subsidies related to R&D projects, contributing to an increase in deferred income by 85.21%[11]. - The company reported a decrease in government subsidy income, with other income falling by 67.16% to 38.55 million from 117.40 million[12]. Market and Product Development - The company is expanding its market presence through the sale of ecological environment monitoring instruments and laboratory analysis instruments[22]. - The company is focusing on market expansion and new product development, with specific strategies to be outlined in upcoming communications[30].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥421,955,548.16, representing a 4.06% increase compared to ¥405,480,042.75 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥519,340.46, a significant decrease of 96.51% from ¥14,883,480.37 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was -¥682,413.79, marking a decline of 104.82% compared to ¥14,145,665.44 in the same period last year[22]. - The net cash flow from operating activities improved by 37.87%, amounting to -¥164,655,746.39, compared to -¥265,031,778.65 in the previous year[22]. - Total assets increased by 11.68% to ¥3,685,940,060.30 from ¥3,300,319,525.95 at the end of the previous year[22]. - Basic earnings per share decreased by 96.67% to ¥0.0010 from ¥0.03 in the same period last year[22]. - The weighted average return on net assets was 0.03%, down from 0.88% in the same period last year, a decrease of 0.85%[22]. - Operating costs increased by 28.36% to ¥249.98 million from ¥194.75 million, indicating rising expenses in production[51]. - Research and development investment decreased by 10.93% to ¥34.50 million from ¥38.73 million, reflecting a reduction in R&D spending[51]. - The company reported a significant increase of 56.38% in cash flow from financing activities, rising to ¥438.02 million from ¥280.11 million, attributed to increased bank loans for PPP projects[51]. Assets and Liabilities - The company's total assets at the end of the reporting period amounted to 3,688,000,000.00 CNY, with a decrease of 1.69% compared to the beginning of the year[62]. - The total liabilities increased to CNY 2,002,599,192.92 as of June 30, 2022, from CNY 1,615,259,894.10 at the beginning of the year, marking an increase of around 23.9%[177]. - Short-term borrowings rose to 377,600,491.75 CNY, an increase of 11.26%, mainly due to increased bank working capital loans[60]. - Long-term borrowings surged to 859,128,180.33 CNY, a significant increase of 98.35%, attributed to loans for the construction of PPP projects[60]. - The company's accounts payable balance was 410,394,777.50 CNY, a decrease of 11.26% from the beginning of the year, primarily due to a reduction in project-related payables[62]. Research and Development - The company has a strong R&D capability, focusing on high-end analytical instruments such as spectrometers and mass spectrometers, with applications in environmental protection and food safety[30]. - The in-vitro diagnostics segment has developed over ten technological achievements in areas such as cardiovascular and infectious disease diagnostics[32]. - The company obtained 6 new patents and had 38 patents accepted, indicating ongoing innovation and development efforts[49]. - Research and development expenses were CNY 34,499,087.76, down 10.3% from CNY 38,730,590.33 in the first half of 2021[185]. Market Position and Strategy - The main business includes analysis and testing instruments, environmental monitoring instruments, and ecological governance, positioning the company as a comprehensive service provider in the analysis instrument industry[29]. - The company emphasizes independent innovation and has accumulated significant technical strength in analytical instruments, aiming to maintain its leadership position in the domestic market[39]. - The domestic analytical instrument industry is expected to grow significantly due to increasing demand and a focus on supply chain security and self-sufficiency[41]. - The company plans to focus on market expansion and new product development to drive future growth[191]. Subsidiaries and Acquisitions - The company has established a subsidiary in Hubei with an investment of CNY 19 million, focusing on environmental product development and consulting services[98]. - The acquisition of Suzhou Tianrui Environmental Technology Co., Ltd. was completed for CNY 135 million, enhancing the company's environmental technology capabilities[96]. - The company holds a 51% stake in Jiangsu Guoce Testing Technology Co., Ltd. after an investment of CNY 43.71 million, further expanding its market presence[98]. - The company acquired a 55.42% stake in Shanghai Panhe Scientific Instrument Co., Ltd. for approximately CNY 168.82 million, increasing its influence in the scientific instrument sector[99]. Shareholder Information - The company’s total shares outstanding are 496,990,870, with 385,447,464 shares being unrestricted and 111,543,406 shares subject to restrictions[156]. - Liu Zhaogui holds 23.41% of the shares, totaling 116,326,306 shares, with no changes during the reporting period[161]. - The total number of ordinary shareholders at the end of the reporting period was 43,651[161]. Corporate Governance - The company held its first extraordinary general meeting of 2022 on March 7, 2022, with an investor participation rate of 33.78%[111]. - There were no changes in the company's board of directors, supervisors, or senior management during the reporting period[112]. - The company did not implement any employee stock ownership plans or other incentive measures during the reporting period[114]. Risks and Challenges - The company faces market competition risks due to the dominance of international firms and severe price competition in the domestic market[106]. - The company acknowledges operational risks associated with large investments and long-term commitments in PPP projects[107]. - The company aims to minimize the impact of goodwill impairment risks from acquisitions by optimizing resource allocation and maintaining competitive advantages[107].

Financial Performance - The company's revenue for Q1 2022 was CNY 245,204,357.32, representing a 17.09% increase compared to CNY 209,411,764.69 in the same period last year[4] - Net profit attributable to shareholders was CNY 25,781,395.95, a significant increase of 67.98% from CNY 15,347,795.32 year-on-year[4] - The basic earnings per share rose to CNY 0.0518, up 67.64% from CNY 0.0309 in the previous year[4] - The net profit for Q1 2022 reached CNY 26,582,104.73, representing a 74.7% increase from CNY 15,215,810.83 in Q1 2021[25] - The earnings per share (EPS) for Q1 2022 was CNY 0.0518, compared to CNY 0.0309 in Q1 2021, reflecting a growth of 67.4%[26] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,568,795,189.11, reflecting a 10.09% increase from CNY 3,241,835,016.69 at the end of the previous year[4] - As of March 31, 2022, the total current assets amounted to CNY 2,847,311,997.03, an increase from CNY 2,561,506,991.89 at the beginning of the year, reflecting a growth of approximately 11.2%[19] - The total liabilities for Q1 2022 were CNY 1,856,995,302.81, up from CNY 1,615,259,894.10 in Q1 2021, indicating a growth of 14.9%[21] - The company's long-term borrowings increased to CNY 524,334,806.80 in Q1 2022, compared to CNY 433,136,806.80 in Q1 2021, marking a rise of 21.1%[21] Cash Flow - The net cash flow from operating activities was negative at CNY -54,461,417.24, a decline of 132.30% compared to CNY -23,443,996.87 in the same period last year[4] - The company reported a decrease in cash inflow from operating activities by 12.03% to CNY 262,802,580.34, mainly due to reduced sales collections[9] - The cash flow from operating activities for Q1 2022 showed a positive trend, contributing to the overall financial health of the company[27] - The net cash flow from operating activities was -54,461,417.24 CNY, compared to -23,443,996.87 CNY in the previous year, indicating a decline in operational cash flow[29] - Total cash inflow from operating activities was 262,802,580.34 CNY, down from 298,732,632.41 CNY year-over-year[29] Operating Costs - The company's operating costs increased by 42.23% to CNY 140,883,574.99, primarily due to the recognition of construction costs for certain PPP project sites[8] - The total operating costs for Q1 2022 were CNY 218,767,156.82, up 13.5% from CNY 192,754,621.92 in the same period last year[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 49,561[11] - The company reported a total of 111,543,406 shares under lock-up agreements, with specific percentages of shares subject to release based on tenure and conditions[16] - The company has a significant number of shareholders, with the top 10 shareholders holding a total of 87,326,306 shares, indicating concentrated ownership[15] - The company is actively managing its shareholding structure, with specific lock-up periods for executives and major shareholders[15] Investment and Other Financial Activities - The company reported an investment income of CNY 100,684.93 for Q1 2022, down from CNY 328,191.78 in Q1 2021[25] - The net cash flow from investing activities was -82,679,152.72 CNY, compared to -221,629,161.73 CNY in the previous year, showing an improvement[30] - The company received 2,539,750.00 CNY from investment absorption, a decrease from 7,500,000.00 CNY in the previous year[30] - The company reported a cash inflow of 35,327,559.52 CNY from investment activities, slightly down from 35,589,446.63 CNY year-over-year[30] Liquidity and Financial Management - The financial data indicates a stable liquidity position despite fluctuations in cash and receivables, suggesting effective asset management strategies[19] - The ending balance of cash and cash equivalents was 297,891,372.25 CNY, down from 438,516,403.86 CNY in the previous year[30] - The cash and cash equivalents decreased to CNY 317,406,964.51 from CNY 330,867,363.67, indicating a decline of about 4.4%[19] Audit Information - The company did not conduct an audit for the first quarter report[31]